Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | CCR5 | P51681 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6037254 | 0.99 | HTR1A (0.51) | HTR1AHTR2ADRD2DRD4SLC6A4 | |
| SCHEMBL6034894 | 0.99 | HTR1A (0.51) | HTR1AHTR2ADRD2DRD4SLC6A4 | |
| SCHEMBL6034533 | 0.97 | DRD2 (0.48) | HTR1AHTR2ADRD2DRD4SLC6A4 | |
| SCHEMBL6034672 | 0.94 | HTR2A (0.48) | HTR1AHTR2ADRD2DRD4SLC6A4 | |
| SCHEMBL6034628 | 0.91 | BCHE (0.47) | HTR1AHTR2ADRD2DRD4SLC6A4 | |
| SCHEMBL6035575 | 0.87 | CCR5 (0.50) | CCR5 | |
| SCHEMBL6034909 | 0.86 | HTR2A (0.45) | HTR1AHTR2ADRD2DRD4SLC6A4 | |
| SCHEMBL6033770 | 0.86 | CCR5 (0.51) | CCR5 | |
| SCHEMBL6034645 | 0.86 | CCR5 (0.51) | CCR5 | |
| SCHEMBL6034941 | 0.85 | DRD2 (0.45) | HTR1AHTR2ADRD2DRD4SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-26 | — | — | US | claimed |
| EP-1553098-A1 | SPIROHETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | claimed |
| EP-1553098-A1 | SPIROHETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS COMPRISING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | CCR1, ACKR3, CCR10 | HTR1A 4432/4885HTR2A 4556/4885DRD2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.